Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study

NCT06682182 is registered in ClinicalTrials.gov with Southwest Hospital, China as lead sponsor.

NCT NCT06682182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study
Lead sponsor
Southwest Hospital, China
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 1, 2028
Enrollment
74 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer with peritoneal metastasis